WO2024027521A1 - Dérivé de méthylophiopogonone a, sa préparation et son utilisation - Google Patents

Dérivé de méthylophiopogonone a, sa préparation et son utilisation Download PDF

Info

Publication number
WO2024027521A1
WO2024027521A1 PCT/CN2023/108779 CN2023108779W WO2024027521A1 WO 2024027521 A1 WO2024027521 A1 WO 2024027521A1 CN 2023108779 W CN2023108779 W CN 2023108779W WO 2024027521 A1 WO2024027521 A1 WO 2024027521A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
group
myocardial
flavonoid
Prior art date
Application number
PCT/CN2023/108779
Other languages
English (en)
Chinese (zh)
Inventor
张金兰
孙华
王冬梅
刘艳鑫
陈子涵
陈智伟
生宁
王喆
郑博文
林莫迪
Original Assignee
中国医学科学院药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医学科学院药物研究所 filed Critical 中国医学科学院药物研究所
Publication of WO2024027521A1 publication Critical patent/WO2024027521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

L'invention concerne un dérivé de méthylophiopogonone A, sa préparation et son utilisation. La présente invention concerne en particulier trois dérivés de méthylophiopogonone A, lesquels dérivés ont les structures chimiques de formule I, de formule II et de formule III ; et un procédé de préparation des dérivés, et l'utilisation des dérivés dans la préparation d'un médicament pour la prévention et/ou le traitement de maladies cardiovasculaires, etc.
PCT/CN2023/108779 2022-07-31 2023-07-23 Dérivé de méthylophiopogonone a, sa préparation et son utilisation WO2024027521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210919793.1 2022-07-31
CN202210919793.1A CN117534661A (zh) 2022-07-31 2022-07-31 甲基麦冬黄酮a类衍生物及其制备和应用

Publications (1)

Publication Number Publication Date
WO2024027521A1 true WO2024027521A1 (fr) 2024-02-08

Family

ID=89784757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/108779 WO2024027521A1 (fr) 2022-07-31 2023-07-23 Dérivé de méthylophiopogonone a, sa préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN117534661A (fr)
WO (1) WO2024027521A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127042A (zh) * 2011-01-26 2011-07-20 浙江大学 一类高异黄酮化合物及制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127042A (zh) * 2011-01-26 2011-07-20 浙江大学 一类高异黄酮化合物及制备方法和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DENG XU, XU JINJU, TONG CHAOYING, SHI FANGYING, SHI SHUYUN: "Homoisoflavonoids profiling of Ophiopogon japonicus by off‐line coupling high‐speed countercurrent chromatography with high‐performance liquid chromatography–diode array detector‒quadrupole time‐of‐flight tandem mass spectrometry", JOURNAL OF SEPARATION SCIENCE, WILEY, DE, vol. 43, no. 8, 1 April 2020 (2020-04-01), DE , pages 1406 - 1414, XP093134723, ISSN: 1615-9306, DOI: 10.1002/jssc.201901222 *
HE FEI, XU BANG-LONG, CHEN CAI, JIA HONG-JING, WU JI-XIONG, WANG XIAO-CHEN, SHENG JIAN-LONG, HUANG LI, CHENG JING: "Methylophiopogonanone A suppresses ischemia/reperfusion-induced myocardial apoptosis in mice via activating PI3K/Akt/eNOS signaling pathway", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 37, no. 6, 1 June 2016 (2016-06-01), GB , pages 763 - 771, XP093134724, ISSN: 1671-4083, DOI: 10.1038/aps.2016.14 *
TEPONNO RÉMY B., PONOU BEAUDELAIRE K., FIORINI DENNIS, BARBONI LUCIANO, TAPONDJOU LÉON A.: "Chemical Constituents from the Roots of Furcraea bedinghausii Koch", INTERNATIONAL LETTERS OF CHEMISTRY, PHYSICS AND ASTRONOMY, vol. 16, 2013, pages 9 - 19, XP093134719, ISSN: 2299-3843, DOI: 10.56431/p-i1m5h3 *
WANG YAN-HUI, QIU CONG, WANG DA-WEI, HU ZHENG-FANG, YU BO-YANG, ZHU DAN-NI: "Identification of multiple constituents in the traditional Chinese medicine formula Sheng-Mai San and rat plasma after oral administration by HPLC–DAD–MS/MS", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, ELSEVIER B.V., AMSTERDAM, NL, vol. 54, no. 5, 1 April 2011 (2011-04-01), AMSTERDAM, NL , pages 1110 - 1127, XP093134715, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2010.11.034 *
YADAV SANTOSH KUMAR: "New Convenient Synthesis of 8-C-Methylated Homoisoflavones and Analysis of Their Structure by NMR and Tandem Mass Spectrometry", INTERNATIONAL JOURNAL OF ORGANIC CHEMISTRY, SCIENTIFIC RESEARCH PUBLISHING, INC., US, vol. 11, no. 01, 1 January 2021 (2021-01-01), US , pages 46 - 54, XP093134704, ISSN: 2161-4687, DOI: 10.4236/ijoc.2021.111005 *

Also Published As

Publication number Publication date
CN117534661A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
US10369131B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
ES2435620T3 (es) Triacetil-3-hidroxifeniladenosina y su uso para regular la grasa en sangre
KR102233081B1 (ko) 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
CN109928972B (zh) 一种苦参碱衍生物及其在药物中的应用
CN107488162B (zh) 一类双环醇类衍生物及其制备和应用
CN103450134B (zh) 香豆素衍生物的制备及其在防治脑部重大疾病中的应用
WO2020001166A1 (fr) Composé glycoside et son procédé de préparation, composition, application et intermédiaire
WO2024027521A1 (fr) Dérivé de méthylophiopogonone a, sa préparation et son utilisation
TW201313679A (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
WO2021103749A1 (fr) Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application
US20230218563A1 (en) Methods for treating or preventing chronic kidney disease
CN111039880B (zh) 咪康唑及其衍生物作为tgr5激动剂的应用
CN113214097B (zh) 治疗阿尔茨海默病的化合物
CN108904481B (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
CN115991702B (zh) 芳基c-葡萄糖苷衍生物、其制备方法及其用途
CN106674245B (zh) 吡喃葡萄糖基衍生物的制备及医药上的应用
CN111825608A (zh) 四氢喹啉类与四氢异喹啉类化合物及其用途
WO2023104201A1 (fr) Dérivé d'aryl c-glucoside, procédé de préparation associé et utilisation correspondante
CN112457284B (zh) 寡聚木脂素类化合物及其制备方法和其药物组合物与用途
CN114685519B (zh) 一类吡喃并咔唑生物碱衍生物及其治疗阿尔茨海默症的用途
CN109694395B (zh) 一种用于缺血再灌注损伤的化合物及其制备方法
CN117736251A (zh) 一类香豆素苷及其制备方法和其药物组合物与用途
CN108853086A (zh) 儿茶素类和表儿茶素类化合物用于上调MicroRNA-150表达水平的用途
TW200302220A (en) Processes and intermediates for preparing glycogen phosphorylase inhibitors
WO2020114457A1 (fr) Inhibiteur de fbpase de sel n-acyl sulfonamide, son procédé de préparation, sa composition pharmaceutique et ses applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23849229

Country of ref document: EP

Kind code of ref document: A1